Nothing Special   »   [go: up one dir, main page]

HK1070063A1 - Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments - Google Patents

Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments Download PDF

Info

Publication number
HK1070063A1
HK1070063A1 HK05102726A HK05102726A HK1070063A1 HK 1070063 A1 HK1070063 A1 HK 1070063A1 HK 05102726 A HK05102726 A HK 05102726A HK 05102726 A HK05102726 A HK 05102726A HK 1070063 A1 HK1070063 A1 HK 1070063A1
Authority
HK
Hong Kong
Prior art keywords
group
polymorph
water
lithium
potassium
Prior art date
Application number
HK05102726A
Other languages
English (en)
Chinese (zh)
Other versions
HK1070063B (en
Inventor
卡洛.博姆巴达
恩里卡.杜比尼
安托万.伊扎亚
海因里希.施奈德
Original Assignee
Sprout Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sprout Pharmaceuticals, Inc. filed Critical Sprout Pharmaceuticals, Inc.
Publication of HK1070063A1 publication Critical patent/HK1070063A1/xx
Publication of HK1070063B publication Critical patent/HK1070063B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26Radicals substituted by carbon atoms having three bonds to hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK05102726.2A 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments HK1070063B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01118593.1 2001-08-02
EP01118593 2001-08-02
EP01130180 2001-12-19
EP01130180.1 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (2)

Publication Number Publication Date
HK1070063A1 true HK1070063A1 (en) 2005-06-10
HK1070063B HK1070063B (en) 2007-03-09

Family

ID=

Also Published As

Publication number Publication date
HRP20040107A2 (en) 2004-06-30
HU228666B1 (en) 2013-05-28
WO2003014079A8 (en) 2003-11-20
PL364598A1 (en) 2004-12-13
ATE288911T1 (de) 2005-02-15
RS50742B (sr) 2010-08-31
KR100899297B1 (ko) 2009-05-26
NZ530510A (en) 2004-07-30
CN1288147C (zh) 2006-12-06
CA2450093A1 (en) 2003-02-20
AU2002331361B2 (en) 2008-06-05
JP2004537597A (ja) 2004-12-16
YU7804A (sh) 2006-08-17
DK1414816T3 (da) 2005-04-11
DE60202958T2 (de) 2006-04-06
SI1414816T1 (en) 2005-06-30
CN1551879A (zh) 2004-12-01
IL159151A0 (en) 2004-06-01
UA76767C2 (uk) 2006-09-15
EP1414816B1 (en) 2005-02-09
WO2003014079A1 (en) 2003-02-20
IL159151A (en) 2009-09-22
HUP0401201A3 (en) 2004-11-29
AR077416A2 (es) 2011-08-24
BR0211601A (pt) 2004-08-24
MXPA04000913A (es) 2004-10-27
JP3822601B2 (ja) 2006-09-20
CA2450093C (en) 2008-09-23
DE60202958D1 (de) 2005-03-17
CO5560572A2 (es) 2005-09-30
PT1414816E (pt) 2005-04-29
EA200400252A1 (ru) 2004-08-26
EA006400B1 (ru) 2005-12-29
HUP0401201A2 (hu) 2004-10-28
MY127294A (en) 2006-11-30
EP1414816A1 (en) 2004-05-06
HRP20040107B1 (hr) 2012-02-29
ES2237694T3 (es) 2005-08-01
EP1518858A1 (en) 2005-03-30
KR20040023704A (ko) 2004-03-18
PL210224B1 (pl) 2011-12-30
AR036208A1 (es) 2004-08-18

Similar Documents

Publication Publication Date Title
KR100899297B1 (ko) 플리반세린의 안정한 다형체, 이의 기술적 제조 방법 및 이를 포함하는 약제학적 조성물
US7420057B2 (en) Stable polymorph of flibanserin
EP1319003B1 (en) Xanthine phosphodiesterase v inhibitors
FI79841C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla aminotetralinderivat.
AU2002331361A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
JP3090305B2 (ja) 2−(2−アミノ−1,6−ジヒドロ−6−オキソ−プリン−9−イル)メトキシ−1,3−プロパンジオール誘導体
AU2001291022A1 (en) Xanthine phosphodiesterase v inhibitors
EP0179855B1 (en) Dopamine agonists
JPH0825997B2 (ja) 3−アミノプロピルオキシフェニル誘導体、その製法およびそれらを含有する医薬組成物
HK1070063B (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US4616011A (en) Novel indole derivatives and pharmaceutical compositions containing same
HK1040399A1 (zh) N-取代的氮雜二環庚烷衍生物及其製備方法和用途
ZA200309586B (en) Stable polymorph of flibanserin technical process for its preparation and the use thereof for preparing medicaments
NO326098B1 (no) Stabil polymorf av flibanserin, teknisk fremgangsmate for fremstilling derav og anvendelse derav for fremstlling av medikamenter
BR122012029907B1 (pt) A crystal polymorphine (form a) of flibanserin 1, its use, process for the preparation of flibanserin 1, and pharmaceutical compositions
IE46273B1 (en) 1-(naphthylethyl)imidazole derivatives
JPH0570467A (ja) アミノ酸置換チアゼトキノリン−3−カルボン酸誘導体
HK1056550B (en) Xanthine phosphodiesterase v inhibitors
EP1790652A1 (en) Polycyclic guanine phosphodiesterase V inhibitors

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF INVENTOR: SCHNEIDER, HEINRICH

Effective date: 20061025

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150730